Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 5.36 | 5.85 | 1.80 | 6.72 | 9.02 | 8.15 | 5.98 | 9.47 | 9.38 | 9.61 | 7.47 | 10.76 |
| Operating costs | 4.62 | 4.95 | 6.13 | 5.86 | 7.91 | 7.29 | 5.17 | 8.55 | 8.44 | 8.85 | 6.46 | 9.90 |
| EBITDA | 0.74 | 0.90 | -4.33 | 0.86 | 1.11 | 0.86 | 0.81 | 0.92 | 0.94 | 0.76 | 1.01 | 0.86 |
| EBITDA margin % | 13.81% | 15.38% | -240.56% | 12.80% | 12.31% | 10.55% | 13.55% | 9.71% | 10.02% | 7.91% | 13.52% | 7.99% |
| Depreciation & amortisation | 0.34 | 0.35 | 0.46 | 0.35 | 0.44 | 0.36 | 0.67 | 0.42 | 0.43 | 0.43 | 0.44 | 0.36 |
| Finance costs | 0.22 | 0.31 | 0.14 | 0.17 | 0.25 | 0.15 | 0.14 | 0.11 | 0.10 | 0.13 | 0.16 | 0.19 |
| Non-operating income | 0.00 | 0.00 | 5.31 | 0.00 | 0.04 | 0.04 | 0.23 | 0.04 | 0.05 | 0.05 | 0.02 | 0.04 |
| Pre-tax profit | 0.18 | 0.24 | 0.38 | 0.34 | 0.46 | 0.39 | 0.23 | 0.43 | 0.46 | 0.25 | 0.43 | 0.35 |
| Effective tax rate % | -61.11% | 0.00% | 89.47% | 26.47% | 26.09% | 25.64% | -60.87% | 25.58% | 28.26% | 28.00% | 0.00% | 25.71% |
| Profit after tax | 0.29 | 0.23 | 0.04 | 0.25 | 0.34 | 0.29 | 0.37 | 0.32 | 0.32 | 0.18 | 0.43 | 0.26 |
| Earnings per share (Rs) |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 17.21 | 17.14 | 16.00 | 14.73 | 16.17 | 8.13 | 17.04 | 20.73 | 18.52 | 29.87 | 35.93 | 37.22 |
| Operating costs | 16.33 | 15.51 | 14.54 | 14.09 | 14.24 | 8.79 | 14.79 | 17.43 | 20.40 | 26.21 | 32.30 | 33.65 |
| EBITDA | 0.88 | 1.63 | 1.46 | 0.64 | 1.93 | -0.66 | 2.25 | 3.30 | -1.88 | 3.66 | 3.63 | 3.57 |
| EBITDA margin % | 5.11% | 9.51% | 9.12% | 4.34% | 11.94% | -8.12% | 13.20% | 15.92% | -10.15% | 12.25% | 10.10% | 9.59% |
| Depreciation & amortisation | 0.59 | 0.70 | 0.62 | 0.52 | 0.43 | 0.65 | 0.78 | 1.39 | 1.48 | 1.84 | 1.72 | 1.66 |
| Finance costs | 0.48 | 1.08 | 0.73 | 0.88 | 1.15 | 0.69 | 0.70 | 1.18 | 0.95 | 0.72 | 0.51 | 0.58 |
| Non-operating income | 0.22 | 0.26 | 0.07 | 1.11 | 0.03 | 2.83 | 0.06 | 0.06 | 5.31 | 0.31 | 0.16 | 0.16 |
| Pre-tax profit | 0.03 | 0.11 | 0.18 | 0.35 | 0.38 | 0.83 | 0.83 | 0.79 | 1.00 | 1.41 | 1.56 | 1.49 |
| Effective tax rate % | 33.33% | 27.27% | 27.78% | 22.86% | 18.42% | 24.10% | 18.07% | -5.06% | 34.00% | 12.06% | 20.51% | |
| Profit after tax | 0.03 | 0.08 | 0.13 | 0.27 | 0.31 | 0.64 | 0.68 | 0.83 | 0.66 | 1.24 | 1.24 | 1.19 |
| Earnings per share (Rs) | ||||||||||||
| Paid out as dividend % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Revenue CAGR | 8% | 35% | 20% | 14% | ||
| Profit CAGR | 45% | 21% | 14% | -10% | ||
| Share price CAGR | % | % | % | -47% | ||
| Average return on equity | -3% | -1% | -6% | 9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net block (property, plant) | 6.58 | 6.01 | 6.40 | 6.07 | 4.73 | 4.41 | 5.51 | 6.85 | 9.10 | 7.70 | 9.37 | 8.45 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.01 | 0.35 | 1.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.31 | 0.31 | 1.79 | 1.79 | 1.80 | 1.89 | 1.89 | 1.89 | 2.05 | 2.05 | 2.05 | 2.05 |
| Current & other assets | 7.63 | 9.04 | 9.45 | 8.41 | 15.25 | 11.82 | 11.48 | 10.32 | 12.56 | 15.41 | 16.26 | 22.42 |
| Total assets | 14.52 | 15.36 | 17.64 | 16.28 | 22.13 | 19.86 | 18.88 | 19.06 | 23.71 | 25.16 | 27.68 | 32.92 |
| Share capital | 4.16 | 4.16 | 4.16 | 4.16 | 4.16 | 4.16 | 4.16 | 4.16 | 4.16 | 4.16 | 4.16 | 4.16 |
| Reserves & surplus | 2.03 | 2.05 | 3.32 | 3.46 | 3.73 | 4.12 | 4.76 | 5.44 | 6.41 | 7.07 | 8.32 | 9.56 |
| Total debt | 5.97 | 6.47 | 7.51 | 5.38 | 10.89 | 7.42 | 5.98 | 4.35 | 8.30 | 5.04 | 2.26 | 7.29 |
| Other liabilities & provisions | 2.36 | 2.68 | 2.65 | 3.28 | 3.35 | 4.16 | 3.98 | 5.11 | 4.84 | 8.89 | 12.94 | 11.91 |
| Equity + liabilities | 14.52 | 15.36 | 17.64 | 16.28 | 22.13 | 19.86 | 18.88 | 19.06 | 23.71 | 25.16 | 27.68 | 32.92 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.20 | -0.14 | 0.82 | 3.12 | -1.43 | 1.21 | 1.40 | 2.03 | 1.28 | -1.13 | 6.69 | -3.86 |
| Investing cash flow | -0.02 | -0.01 | -0.77 | -0.25 | 1.65 | -1.50 | 2.79 | -2.11 | -3.63 | 5.17 | -3.26 | -0.65 |
| Free cash flow (after capex) | -0.70 | -0.68 | 0.05 | 2.86 | 0.22 | -0.29 | 4.19 | -0.09 | -2.36 | 4.01 | 3.35 | -4.66 |
| Financing cash flow | -0.81 | 0.19 | -0.08 | -2.80 | 4.74 | -4.74 | -2.16 | -1.78 | 2.77 | -4.20 | -3.50 | 4.52 |
| Net change in cash | -1.03 | 0.05 | -0.03 | 0.06 | 4.96 | -5.03 | 2.03 | -1.86 | 0.41 | -0.17 | -0.06 | 0.01 |
| Cash conversion (OCF / EBITDA) % | -6% | -14% | 53% | 218% | -212% | 66% | -232% | 96% | 39% | 45% | 189% | -95% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on capital employed % | 8.93% | 4.11% | 8.60% | 6.50% | 1.57% | 8.87% | -8.30% | 10.61% | 12.00% | -18.61% | 12.77% | 11.58% |
| Receivable days | 46.63 | 57.69 | 49.40 | 74.14 | 85.49 | 107.22 | 120.32 | 72.61 | 75.54 | 50.85 | 79.92 | 116.21 |
| Inventory days | 16.83 | 73.23 | 98.98 | 217.45 | 49.38 | 41.71 | 225.64 | 211.14 | 130.50 | |||
| Payable days | 138.49 | 120.54 | 143.83 | 481.49 | 390.76 | 304.84 | 1,659.09 | 418.28 | 164.76 | |||
| Cash cycle (days) | -75.04 | 10.37 | 49.40 | 29.29 | 85.49 | 107.22 | -143.72 | -268.77 | -187.59 | -1,382.61 | -127.23 | 81.96 |
| Working capital days | 100.40 | 27.15 | 20.87 | 18.71 | -75.08 | 46.50 | 48.04 | 35.99 | -2.64 | -115.89 | 2.69 | 15.64 |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter group % | 53.63% | 53.63% | 53.63% | 53.63% | 53.63% | 53.63% | 53.63% | 53.63% | 53.63% | 53.63% | 53.63% | 53.63% |
| Retail & others % | 46.37% | 46.37% | 46.37% | 46.37% | 46.38% | 46.37% | 46.37% | 46.37% | 46.37% | 46.36% | 46.37% | 46.37% |
| Shareholder count | 3,698 | 3,698 | 3,698 | 3,697 | 3,778 | 3,967 | 4,068 | 4,147 | 4,377 | 4,226 | 4,210 | 4,211 |
Fundamentals
Market value₹ 28.2 Cr.
Last price₹ 86.0
P/E (trailing)23.7
Book value / share₹
Return on capital11.6 %
Return on equity9.47 %
Dividend yield0.00 %
Face value₹ 10.0
Revenue CAGR (TTM)14%
Profit CAGR (TTM)-10%
Standalone figures.
Valuation
Market capRs 37 Cr
Enterprise valueRs 43 Cr
P/E (TTM)30.73x
Price to book2.67x
Price to sales0.98x
EV / EBITDA11.64x
EV / EBIT20.97x
EV / sales1.17x
Earnings yield3.25%
P/E, 3-year average29.83x
P/B, 3-year average2.81x
P/E, 5-year average29.83x
P/B, 5-year average2.81x
Profitability
Operating margin (excl. other income)10.10%
Operating margin (incl. other income)10.55%
EBITDA margin10.02%
Pre-tax margin4.00%
Net profit margin3.20%
Net margin, latest quarter2.42%
ROE9.47%
ROCE11.58%
ROA4.09%
ROE, 3-year average8.66%
ROCE, 3-year average12.14%
ROA, 3-year average3.83%
ROE, 5-year average8.31%
ROCE, 5-year average11.81%
ROA, 5-year average3.79%
ROIC (approx.)8.00%
Tax rate20.51%
Other income / net worth1.17%
Growth
Sales growth (latest year)20.29%
Profit growth (latest year)0.00%
Sales CAGR, 3 years20.12%
Sales CAGR, 5 years34.61%
Profit CAGR, 3 years14.32%
Profit CAGR, 5 years14.14%
Sales growth QoQ44.04%
Profit growth QoQ-39.53%
Sales growth YoY (latest quarter)13.62%
Profit growth YoY (latest quarter)-18.75%
Per share
EPS (TTM)Rs 2.86
EPS (latest year)Rs 2.98
EPS (latest quarter)Rs 0.63
EPS, 3-year averageRs 2.52
EPS, 5-year averageRs 2.24
Book value per shareRs 33.00
Sales per shareRs 89.53
Cash flow per shareRs -9.28
Efficiency
Asset turnover1.09x
Fixed asset turnover4.25x
Inventory turnover8.31x
Inventory days44 days
Debtor days116 days
Debtors turnover3.14x
Leverage
Total debtRs 7 Cr
Cash and bankRs 0 Cr
Net debtRs 7 Cr
Debt to equity0.53x
Net debt / EBITDA1.83x
Interest coverage3.57x
Owners' fund to total sources41.68%
Debt to assets22.14%
Cash flow
Operating cash flow (latest year)Rs -4 Cr
Investing cash flow (latest year)Rs -1 Cr
Financing cash flow (latest year)Rs 5 Cr
Net change in cash (latest year)Rs 0 Cr
Statement figures
Net sales (TTM)Rs 37 Cr
Net sales (latest year)Rs 36 Cr
Sales (latest quarter)Rs 11 Cr
Operating profit excl. other income (latest year)Rs 4 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 4 Cr
PBDT (TTM)Rs 3 Cr
Profit before tax (TTM)Rs 1 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 1 Cr
Net profit (latest year)Rs 1 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 2 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 27 Cr
Total expenditure (latest year)Rs 32 Cr
Total income (latest year)Rs 36 Cr
Share capitalRs 4 Cr
ReservesRs 10 Cr
Shareholders' fundsRs 14 Cr
Total assetsRs 33 Cr
Net blockRs 8 Cr
InvestmentsRs 2 Cr
ReceivablesRs 11 Cr
InventoryRs 3 Cr
Other liabilitiesRs 12 Cr
Shares outstanding (crore)0.42
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 30.7 is at the 11th percentile of its own 2.3-year range
(median 35.5, low 25.4, high 81.2).
P/B 2.67 is at the 14th percentile (median 3.02).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 524548 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -1.7% | -2.8% | +1.0 pts |
| 1 month | -9.2% | -6.8% | -2.4 pts |
| 3 months | -15.8% | -7.6% | -8.2 pts |
Red flags
F-score 3 of 8| explain | High accruals Profit exceeded operating cash by 15% of total assets in 2026 |
| explain | Receivables outrunning sales Receivables grew 75% vs sales +20% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹11 Cr +13.6% vs Jun 2025.
Net profit ₹0 Cr -18.8%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Dr Lal Pathlabs Ltd | 32,737 | 58.2 | 28.0 % |
| Vijaya Diagnostic Centre Ltd | 15,192 | 81.0 | 20.5 % |
| Metropolis Healthcare Ltd | 11,665 | 56.0 | 17.8 % |
| Thyrocare Technologies Ltd | 8,708 | 48.2 | 35.4 % |
| Nephrocare Health Services Ltd | 6,671 | 78.4 | 15.3 % |
| Suraksha Diagnostic Ltd | 1,847 | 51.6 | 17.3 % |
| Krsnaa Diagnostics Ltd | 1,791 | 18.1 | 12.7 % |
| 3B Blackbio DX Ltd | 1,396 | 25.1 | 25.5 % |
| One Global Service Provider Ltd | 1,046 | 14.1 | 87.0 % |
| Health X Platform Ltd | 923 | 0.03 % | |
| Gaudium IVF and Women Health Ltd | 830 | 35.9 | 29.3 % |
| Chandan Healthcare Ltd | 581 | 22.1 | 23.3 % |
| Pramodini Medicare Ltd | 259 | 14.9 | 41.8 % |
| Aspira Pathlab & Diagnostics Ltd | 148 | 2.84 % | |
| Choksi Laboratories Ltd | 132 | 69.2 | 9.44 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Sharma East India Hosp and Medical Research Ltd?
Sharma East India Hosp and Medical Research Ltd (524548) has a market capitalisation of Rs 28.2 Cr. at the 2026-10-01 close.
What is the P/E ratio of Sharma East India Hosp and Medical Research Ltd?
Sharma East India Hosp and Medical Research Ltd trades at a P/E of 23.7 on trailing twelve-month profit, at the 2026-10-01 close.
What were Sharma East India Hosp and Medical Research Ltd's latest quarterly results?
In the Jun 2026 quarter, Sharma East India Hosp and Medical Research Ltd sales was Rs 11 Cr (+13.6% vs Jun 2025) and net profit was Rs 0 Cr.